Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Athersys, Inc." (ATHX) Report Updated: Feb 01, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Athersys, Inc." (ATHX)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: SPHS, EXEL, EBS, ANAC

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

"Athersys, Inc."© quotemedia

Company Profile

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company’s lead platform product, MultiStem is an allogeneic stem cell product, which is evaluated in 2 completed Phase I clinical trials and in 2 ongoing Phase II clinical trials for regenerative medicine and stem cell therapy applications. The company is also involved in the development of pharmaceuticals to treat obesity, and related metabolic conditions, such as diabetes and neurological indications; and small molecule compounds. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market; and Bristol-Myers Squibb to provide cell lines expressing validated drug targets produced using the company’s RAGE technology for compound screening and development. The company was founded in 1995 and is based in Cleveland, Ohio.

Recent News: "Athersys, Inc."